3-Hydroxyphencyclidine (3-HO-PCP) is a dissociative anesthetic that has been sold online as a designer drug. 3-HO-PCP binds to the NMDA and opioid receptors. On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a reportabout methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-HO-PCP.